90 related articles for article (PubMed ID: 22850619)
21. Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway.
Shaikh IA; Brown I; Schofield AC; Wahle KW; Heys SD
Prostate; 2008 Nov; 68(15):1635-46. PubMed ID: 18668525
[TBL] [Abstract][Full Text] [Related]
22. Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells.
Siddiqui RA; Zerouga M; Wu M; Castillo A; Harvey K; Zaloga GP; Stillwell W
Breast Cancer Res; 2005; 7(5):R645-54. PubMed ID: 16168109
[TBL] [Abstract][Full Text] [Related]
23. Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells.
Horia E; Watkins BA
Carcinogenesis; 2007 Apr; 28(4):809-15. PubMed ID: 17052999
[TBL] [Abstract][Full Text] [Related]
24. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
25. Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial.
Hamazaki K; Itomura M; Huan M; Nishizawa H; Sawazaki S; Tanouchi M; Watanabe S; Hamazaki T; Terasawa K; Yazawa K
Nutrition; 2005 Jun; 21(6):705-10. PubMed ID: 15925295
[TBL] [Abstract][Full Text] [Related]
26. Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting proinflammatory mediator production and transcription from LPS-induced human asthmatic alveolar macrophage cells.
Mickleborough TD; Tecklenburg SL; Montgomery GS; Lindley MR
Clin Nutr; 2009 Feb; 28(1):71-7. PubMed ID: 19054597
[TBL] [Abstract][Full Text] [Related]
27. The differential effects of EPA and DHA on cardiovascular risk factors.
Cottin SC; Sanders TA; Hall WL
Proc Nutr Soc; 2011 May; 70(2):215-31. PubMed ID: 21349231
[TBL] [Abstract][Full Text] [Related]
28. Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin.
Duncan RE; El-Sohemy A; Archer MC
Cancer Lett; 2005 Jun; 224(2):221-8. PubMed ID: 15914273
[TBL] [Abstract][Full Text] [Related]
29. Promotive effects of hyperthermia on the inhibition of DNA synthesis in ehrlich ascites tumor cells by eicosapentaenoic and docosahexaenoic acids.
Tanaka H; Kageyama K; Kimura M; Iwamoto SI; Ueno Y; Asagi K; Asada R; Miwa N
Exp Oncol; 2006 Sep; 28(3):203-8. PubMed ID: 17080013
[TBL] [Abstract][Full Text] [Related]
30. PPARalpha signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells.
Tuller ER; Brock AL; Yu H; Lou JR; Benbrook DM; Ding WQ
Biochem Pharmacol; 2009 May; 77(9):1480-6. PubMed ID: 19426685
[TBL] [Abstract][Full Text] [Related]
31. n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway.
Calviello G; Di Nicuolo F; Gragnoli S; Piccioni E; Serini S; Maggiano N; Tringali G; Navarra P; Ranelletti FO; Palozza P
Carcinogenesis; 2004 Dec; 25(12):2303-10. PubMed ID: 15358633
[TBL] [Abstract][Full Text] [Related]
32. Study of in vitro and in vivo effect of docosahexaenoic acid on rat C6 glioma.
Nasrollahzadeh J; Siassi F; Doosti M; Eshraghian MR
J Exp Ther Oncol; 2009; 8(2):95-103. PubMed ID: 20192116
[TBL] [Abstract][Full Text] [Related]
33. Effects of essential fatty acid deficiency and supplementation with docosahexaenoic acid (DHA; 22:6n-3) on cellular fatty acid compositions and fatty acyl desaturation in a cell culture model.
Tocher DR; Dick JR
Prostaglandins Leukot Essent Fatty Acids; 2001 Jan; 64(1):11-22. PubMed ID: 11161581
[TBL] [Abstract][Full Text] [Related]
34. Synergistic Effect of Eicosapentaenoic Acid on Antiproliferative Action of Anticancer Drugs in a Cancer Cell Line Model.
Ogo A; Miyake S; Kubota H; Higashida M; Matsumoto H; Teramoto F; Hirai T
Ann Nutr Metab; 2017; 71(3-4):247-252. PubMed ID: 29136623
[TBL] [Abstract][Full Text] [Related]
35. Adding pharmacogenomics to the development of new marine-derived anticancer agents.
Jimeno J; Aracil M; Tercero JC
J Transl Med; 2006 Jan; 4():3. PubMed ID: 16401350
[TBL] [Abstract][Full Text] [Related]
36. Multidrug Resistance and Prodrug Activation for Cancer Gene Therapy of Breast Cancer.
Fujii T; Fu SQ; Yin LH; Nanakorn T; Sanchez FG; Cooperberg M; Guo D; Wang T; D L; Pizzorno G; Deisseroth A
Breast Cancer; 1997 Dec; 4(4):210-212. PubMed ID: 11091601
[TBL] [Abstract][Full Text] [Related]
37. Sensitization strategies in lung cancer.
Zhang XY; Zhang P
Oncol Lett; 2016 Nov; 12(5):3669-3673. PubMed ID: 27900051
[TBL] [Abstract][Full Text] [Related]
38. Omega-3 fatty acids in cancer.
Laviano A; Rianda S; Molfino A; Rossi Fanelli F
Curr Opin Clin Nutr Metab Care; 2013 Mar; 16(2):156-61. PubMed ID: 23299701
[TBL] [Abstract][Full Text] [Related]
39. Omega-3 Fatty Acids and Cancer Cell Cytotoxicity: Implications for Multi-Targeted Cancer Therapy.
D'Eliseo D; Velotti F
J Clin Med; 2016 Jan; 5(2):. PubMed ID: 26821053
[TBL] [Abstract][Full Text] [Related]
40. Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials.
Nabavi SF; Bilotto S; Russo GL; Orhan IE; Habtemariam S; Daglia M; Devi KP; Loizzo MR; Tundis R; Nabavi SM
Cancer Metastasis Rev; 2015 Sep; 34(3):359-80. PubMed ID: 26227583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
